Steven M. Fruchtman - Feb 7, 2024 Form 4 Insider Report for Onconova Therapeutics, Inc. (ONTX)

Role
PRESIDENT, CHIEF EXECUTIVE OFF, Director
Signature
/s/ Mark Guerin, Attorney-in-Fact
Stock symbol
ONTX
Transactions as of
Feb 7, 2024
Transactions value $
-$6,172
Form type
4
Date filed
2/9/2024, 05:36 PM
Previous filing
Aug 4, 2023
Next filing
Mar 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONTX Common Stock Options Exercise +21.3K +44.14% 69.6K Feb 7, 2024 Direct F1
transaction ONTX Common Stock Tax liability -$6.17K -9.21K -13.23% $0.67 60.4K Feb 7, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ONTX Restricted Stock Units Options Exercise $0 -21.3K -50% $0.00 21.3K Feb 7, 2024 Common Stock 21.3K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 On February 7, 2022 the reporting person was granted 63,960 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.